This company has been acquired
The company may no longer be operating, as it has been acquired. Find out why through their latest events.
이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!
Pardes Biosciences 미래 성장
Future 기준 확인 0/6
We currently don't have sufficient analyst coverage to forecast growth and revenue for Pardes Biosciences.
주요 정보
36.6%
수익 성장률
39.3%
EPS 성장률
| Biotechs 수익 성장 | 24.2% |
| 매출 성장률 | n/a |
| 향후 자기자본 수익률 | n/a |
| 애널리스트 커버리지 | Low |
| 마지막 업데이트 | 17 Jul 2023 |
최근 미래 성장 업데이트
Recent updates
We're Keeping An Eye On Pardes Biosciences' (NASDAQ:PRDS) Cash Burn Rate
Jul 18
Here's Why We're Watching Pardes Biosciences' (NASDAQ:PRDS) Cash Burn Situation
Jan 20We Think Pardes Biosciences (NASDAQ:PRDS) Needs To Drive Business Growth Carefully
Oct 01Pardes begins phase 2 trial of oral drug PBI-0451 for COVID-19
Sep 13Pardes Biosciences GAAP EPS of -$0.48
Aug 15Pardes Biosciences (NASDAQ:PRDS) Is In A Good Position To Deliver On Growth Plans
Jun 14Pardes Biosciences: Advancing A Viral Protease Inhibitor Platform
Jan 21수익 및 매출 성장 예측
| 날짜 | 수익 | 수익 | 잉여 현금 흐름 | 작전 현금 | 평균 애널리스트 수 |
|---|---|---|---|---|---|
| 12/31/2025 | N/A | -34 | N/A | N/A | 1 |
| 12/31/2024 | N/A | -33 | N/A | N/A | 1 |
| 12/31/2023 | N/A | -77 | N/A | N/A | 1 |
| 6/30/2023 | N/A | -76 | -79 | -79 | N/A |
| 3/31/2023 | N/A | -93 | -78 | -78 | N/A |
| 12/31/2022 | N/A | -97 | -72 | -72 | N/A |
| 9/30/2022 | N/A | -87 | -76 | -76 | N/A |
| 6/30/2022 | N/A | -75 | -67 | -67 | N/A |
| 3/31/2022 | N/A | -55 | -54 | -54 | N/A |
| 12/31/2021 | N/A | -39 | -37 | -37 | N/A |
| 9/30/2021 | N/A | -36 | -23 | -23 | N/A |
| 6/30/2021 | N/A | -27 | -14 | -14 | N/A |
| 3/31/2021 | N/A | -20 | -8 | -8 | N/A |
애널리스트 미래 성장 예측
수입 대 저축률: PRDS is forecast to remain unprofitable over the next 3 years.
수익 vs 시장: PRDS is forecast to remain unprofitable over the next 3 years.
고성장 수익: PRDS is forecast to remain unprofitable over the next 3 years.
수익 대 시장: Insufficient data to determine if PRDS's revenue is forecast to grow faster than the US market.
고성장 수익: PRDS is forecast to have no revenue next year.
주당 순이익 성장 예측
미래 자기자본 수익률
미래 ROE: Insufficient data to determine if PRDS's Return on Equity is forecast to be high in 3 years time